Mitomycin (Mitomycin) 40 mg

Used in the treatment of:

• Peritoneal Carcinomatosis: Via intraperitoneal administration (HIPEC) for gastric or colorectal cancer.
• Bladder Cancer: High-dose intravesical therapy.
• Systemic Cancer: Gastric, Pancreatic, and Anal cancers (IV route).

⚠️ DANGER: Potent Vesicant. Handle with extreme care.

Reconstitution of 40 mg Vial:

• Usually reconstituted with 40 ml of Sterile Water or Saline to achieve a concentration of 1 mg/ml.
• Ensure complete dissolution before administration.

Administration: Intravenous (IV), Intravesical, or Intraperitoneal. NEVER intramuscular or subcutaneous (causes severe gangrene/necrosis).

• Coagulation disorders or increased bleeding tendency.
• Severe bone marrow depression.
• Pregnancy (Teratogenic).
• Acute infection.

Delayed Toxicity Warning:

Myelosuppression (low blood counts) is delayed and cumulative. The nadir (lowest point) usually occurs 4-6 weeks after therapy. Dose adjustments are often required for subsequent cycles.

Other risks: Hemolytic Uremic Syndrome (HUS), interstitial pneumonia.